Preventing Fractures in Diabetic Dialysis Patients

authors:

avatar E. Michael Lewiecki 1 , *

New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico, USA
International Journal of Endocrinology and Metabolism: Vol.10, issue 4; 640-641
published online: September 29, 2012
article type: Letter
received: May 2, 2012
revised: May 14, 2012
accepted: May 15, 2012
DOI: https://doi.org/10.5812/ijem.5384

how to cite: Lewiecki E M. Preventing Fractures in Diabetic Dialysis Patients. Int J Endocrinol Metab. 2012;10(4): 640-641. https://doi.org/10.5812/ijem.5384.

References

  • 1.

    Montagnani A, Gonnelli S, Alessandri M, Nuti R. Osteoporosis and risk of fracture in patients with diabetes: an update. Aging Clin Exp Res. 2011;23(2):84-90. [PubMed ID: 21743287].

  • 2.

    Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180(1):32-9. [PubMed ID: 19073651]. https://doi.org/10.1503/cmaj.080486.

  • 3.

    Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008;74(6):721-31. [PubMed ID: 18563052]. https://doi.org/10.1038/ki.2008.264.

  • 4.

    Jamal SA, West SL, Miller PD. Bone and kidney disease: diagnostic and therapeutic implications. Curr Rheumatol Rep. 2012;14(3):217-23. [PubMed ID: 22350608]. https://doi.org/10.1007/s11926-012-0243-9.

  • 5.

    Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando Y, et al. Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients With Type 2 Diabetes. Int J Endocrinol Metab. 2012;10(2):464-9. https://doi.org/10.5812/ijem.3794.